Treatment in patients with acute myeloid leukemia/high‐risk myelodysplastic syndrome with hypomethylating agents: Day‐hospital management compared to home care setting
European Journal of Haematology · 2023
DOI: 10.1111/ejh.14012 ↗Kurz gefasst
Fachartikel in der Zeitschrift European Journal of Haematology, 2023. Verfasst von Giulio Trapè und 24 weiteren Autor:innen. Beteiligte Einrichtung: Hematology Unit-ASL Viterbo, Belcolle Hospital, Viterbo, Italy. Hauptthemen laut MEDLINE: Myelodysplastic Syndromes, Leukemia, Myeloid, Acute. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 14 Literaturangaben.
Themen: Ambulante Pflege
Abstract (Originalsprache)
Objectives
Aim of the study was to evaluate the role of a Domiciliary Hematologic Care Unit (DHCU) compared to standard DH setting in the active frontline treatment with hypomethylating agents (HMAs) +/− venetoclax of frail patients with acute myelogenous leukemia/high‐risk myelodysplastic syndromes (AML/HR‐MDS).
Methods
All patients with newly diagnosed AML/HR‐MDS unfit for intensive care and treated frontline with HMAs from January 2010 to April 2021 were retrospectively included.
Results
Among 112 patients (62 AML/50 HR‐MDS), 69 (61.6%) were treated in a standard DH setting and 43 (38.4%) were followed by DHCU, allocated to DH or DHCU by responsible physician. Overall response rate was 29/69 (42.0%) in DH versus 19/43 (44.1%) in DHCU ( p = .797). Median response duration was 8.7 months (95%CI 7.0–10.3) in DH versus 13.0 months (95%CI 8.3–17.6) in DHCU ( p = .460). Infections were also equally reported. Median overall survival of patients treated in DH was 13.7 months (95%CI 9.9–17.4) compared to 13.0 months (95%CI 6.7–19.3) of patients managed by DHCU ( p = .753).
Conclusions
Home care management of HMA is feasible and effective, with results similar to standard DH setting: this approach is thus adequate to offer active therapies in frail patients with AML/HR‐MDS considered up to now ineligible.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Hematology Unit-ASL Viterbo, Belcolle Hospital, Viterbo, Italy.
- Laboratory of Immunophenotyping-ASL Viterbo, Belcolle Hospital, Viterbo, Italy.
- Laboratory of Medical Genetics-ASL Viterbo, Ospedale Belcolle, Viterbo, Italy.
ORCID-Profile: Roberto Latagliata
Zitieren
APA
Trapè, G., De Angelis, G., Morucci, M., Tarnani, M., De Gregoris, C., Di Veroli, A., Panichi, V., Topini, G., Bassi, L., Isidori, R., Poscente, M., Innocenti, V., Cippitelli, E. E., Talucci, R., Bertelli, S., Crocicchia, A., Lippi, A., Pezzuti, G., Fuschino, M., …, & Latagliata, R. (2023). Treatment in patients with acute myeloid leukemia/high‐risk myelodysplastic syndrome with hypomethylating agents: Day‐hospital management compared to home care setting. European Journal of Haematology. https://doi.org/10.1111/ejh.14012
Vancouver
Trapè G, De Angelis G, Morucci M, Tarnani M, De Gregoris C, Di Veroli A, et al. Treatment in patients with acute myeloid leukemia/high‐risk myelodysplastic syndrome with hypomethylating agents: Day‐hospital management compared to home care setting. European Journal of Haematology. 2023. doi:10.1111/ejh.14012
BibTeX
@article{Trap2023,
author = {Trapè, Giulio and De Angelis, Gioia and Morucci, Marco and Tarnani, Michela and De Gregoris, Cinzia and Di Veroli, Ambra and Panichi, Valentina and Topini, Giuseppe and Bassi, Loredana and Isidori, Raffaella and Poscente, Monica and Innocenti, Vincenza and Cippitelli, Elisa Emanueli and Talucci, Roberta and Bertelli, Silvia and Crocicchia, Alessandra and Lippi, Annalisa and Pezzuti, Giulia and Fuschino, Michela and Randi, Raffaella and Mastini, Cristina and Ciambella, Silvia and Pessina, Gloria and Montanaro, Marco and Latagliata, Roberto},
title = {Treatment in patients with acute myeloid leukemia/high‐risk myelodysplastic syndrome with hypomethylating agents: Day‐hospital management compared to home care setting},
journal = {European Journal of Haematology},
year = {2023},
doi = {10.1111/ejh.14012}
}
EUVIMED